CD3 binding molecules

Customized antigen-binding proteins with tailored CD3-binding properties address the limitations of existing antibodies, enabling targeted T cell engagement for tumor therapy or autoimmune modulation with improved specificity and reduced cytotoxicity.

JP7783860B2Active Publication Date: 2025-12-10MELS BE FE
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023158375
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-10-01
Filing Date
2023-09-22
Publication Date
2025-12-10
Estimated Expiration
2040-03-27

AI Technical Summary

Technical Problem

Existing monoclonal CD3-binding antibodies for therapeutic use have limitations in terms of affinity and cytotoxicity, which affect their suitability for immuno-oncology and autoimmune applications, necessitating the development of antibodies with tailored binding properties for specific therapeutic effects.

Method used

Development of antigen-binding proteins, particularly antibodies, with customized heavy and light chain variable regions and CDR sequences to achieve either high affinity with low cytotoxicity or low affinity with high cytotoxicity, suitable for engaging or downregulating T cells, and capable of binding additional membrane-bound molecules.

Benefits of technology

The customized antibodies provide enhanced therapeutic efficacy by selectively targeting T cells for tumor treatment or autoimmune regulation, with improved specificity and reduced off-target effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007783860000006
    Figure 0007783860000006
  • Figure 0007783860000007
    Figure 0007783860000007
  • Figure 0007783860000008
    Figure 0007783860000008
Patent Text Reader

Abstract

To provide antibodies for the treatment of tumors, preferably bispecific or multispecific antibodies.SOLUTION: The present invention provides an antigen-binding protein that binds human CD3, comprising an antibody variable domain comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3 comprising the following amino acid sequences: CDR1 : SFGIS, CDR2: GFIPVLGTANYAQKFQG and CDR3: RGNWNPFDP, or comprising the amino acid sequences: CDR1: SX1TFTIS, CDR2: GIIPX2FGTITYAQKFQG, and CDR3: RGNWNPFDP (where X1=K or R, X2=L or I).SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • human cd3 binding antibody

    JP2018520169A